European Patent Office

T 1828/20 (Rifaximin formulation / ALPHASIGMA) of 27.09.2022

European Case Law Identifier
ECLI:EP:BA:2022:T182820.20220927
Date of decision
27 September 2022
Case number
T 1828/20
Online on
5 October 2022
Petition for review of
-
Application number
11776879.6
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN, PROCESSES FOR THEIR OBTAINMENT AND METHOD OF TREATING INTESTINAL DISEASE
Applicant name
Alfasigma S.p.A.
Opponent name
Sandoz GmbH
Board
3.3.07
Headnote
-
Relevant legal provisions
European Patent Convention Art 113(2)
Keywords
Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Catchword
-
Cited cases
-
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.